SCHEMBL5887472

SCHEMBL5887472

CS(=O)(=O)C1=CC[CH]C(c2ccc(Oc3ccccc3)cc2)=C1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PGR P06401 2/20 0.41
PTGS2 P35354 3/20 0.40
PTGS1 P23219 2/20 0.39
NPC1 O15118 1/20 0.38
HTT P42858 4/20 0.38
LMNA P02545 2/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
GSTP1 P09211 1/20 0.37
SOS1 Q07889 1/20 0.37
CA1 P00915 1/20 0.37
CA2 P00918 1/20 0.37
CA9 Q16790 1/20 0.37
HPGD P15428 1/20 0.35
LTA4H P09960 1/20 0.35
ADAMTS4 O75173 1/20 0.34
BCL2L1 Q07817 1/20 0.34
MCL1 Q07820 1/20 0.34
GAA P10253 1/20 0.34
TSHR P16473 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5886926 0.77 LTA4H (0.47) NPC1HTTSMN1; SMN2GSTP1LTA4H
SCHEMBL4808505 0.74 LTA4H (0.37) NPC1LMNAGSTP1HPGDLTA4H
SCHEMBL7359540 0.66 SOS1 (0.64) PGRPTGS2PTGS1HTTLMNA
SCHEMBL1676176 0.65 PTGS2 (0.63) PTGS2PTGS1HTTLMNASMN1; SMN2
SCHEMBL6406035 0.62 LTA4H (0.75) NPC1GSTP1SOS1CA1CA2
SCHEMBL2860844 0.62 LTA4H (0.75) NPC1GSTP1SOS1CA1CA2
SCHEMBL197414 0.62 LTA4H (0.75) NPC1GSTP1SOS1CA1CA2
SCHEMBL3376915 0.62 PGR (0.90) PGRNPC1HTTSMN1; SMN2HPGD
SCHEMBL9452130 0.61 HTT (0.72) PGRPTGS2HTTLMNASMN1; SMN2
SCHEMBL9155335 0.61 SOS1 (0.56) PGRPTGS2HTTLMNASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7037931-B2 Corticotropin releasing factor moderator; analgesics; drug abruse, drug dependency; schizophrenia JANSSEN PHARMACEUTICA N.V. (BE) 2006-05-02 US claimed
JP-2006501194-A 2006-01-12 JP claimed
EP-1525190-A1 CCK-1 RECEPTOR MODULATORS JANSSEN PHARMACEUTICA N.V. (BE) 2005-04-27 EP claimed
WO-2004007463-A1 CCK-1 RECEPTOR MODULATORS JANSSEN PHARMACEUTICA, N.V. (BE) 2004-01-22 WO claimed
US-20060004195-A1 Alpha,beta-unsaturated esters and acids by stereoselective dehydration JANSSEN PHARMACEUTICA N.V. (BE) 2006-01-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060004195-A1 Alpha,beta-unsaturated esters and acids by stereoselective dehydration CCKAR, CCKBR, FFAR1 PGR 212/4885PTGS2 1436/4885PTGS1 471/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.